Signals Analytics Powers Informa Pharma Intelligences Offerings With Next Generation Advanced Analytics
NEW YORK, April 22, 2020 (GLOBE NEWSWIRE) -- Informa Pharma Intelligence, the global business intelligence provider for the biopharma industry, and Signals Analytics, the next generation advanced analytics platform that leverages external data to uncover trends and novel insights, today announced a joint offering that helps life sciences companies to identify new opportunities, mitigate investment risks and accelerate the drug development process. The combined solution leverages Signals Analytics AI-engines with Informa Pharma Intelligences industry leading R&D and commercial intelligence services to provide customers with timely, relevant and complete insights.
Informa Pharma Intelligence will utilize their best-in-class content and Signals Analytics powerful deep learning technology approach to launch three new Apps focused on supporting earlier stage evaluation and prioritization. The Apps created will provide life sciences companies with a 360-degree market view, configured with smart contextual engines to drive actionable business decisions. The solution includes the following Apps:
Target Prioritization: Using Pharma Intelligence databases such as Pharmaprojects, Trialtrove and Biomedtracker as well as public forums, the App will evaluate molecular development by stage, therapeutic potential and the competitive landscape. In turn, users will have access to a comprehensive library of insights that evaluate the commercial success and risk factors of an asset.
Modality Innovation: Utilizing a harmonized and comprehensive combination of public sources and Pharma Intelligences leading databases, this App provides an analysis from the perspective of the individual modality and provides a maturity score. In turn, users can establish which modalities should be prioritized when investigating trending technology solutions.
Competitive Benchmarking: Key insights are derived here around how organizations benchmark against one another relative to drugs, trials, events, patents and more. In turn, users can gain an overview of competitors medical condition pipeline, which target molecules, and what modalities they are working on.
The ability of AI to fuel drug development for complex conditions and rare diseases and drive commercial success makes platforms like Signals Analytics critical for managing business lifecycle decisions, said Ramsey Hashem, Chief Commercial Officer, Informa Pharma Intelligence. Due to the high cost and long development cycles, creating new drugs of any kind is a long and expensive process filled with uncertainty. Its essential that stakeholders have access to timely, accurate and relevant novel insights in order to not just mitigate risk but also significantly reduce costs and time-to-market. While Informa Pharma Intelligence is able to provide the high quality of information needed to make these decisions, Signals Analytics will help harmonize our data in order to provide users with a truly advanced analytics solution.
According to Markets and Markets, the AI in drug discovery market is projected to grow at a CAGR of 40.8% in the coming years. This growth is driven by the need to connect and analyze new data sets, control drug development and discovery costs, reduce the overall development cycle, address the high failure rates, manage the impending patent expiration of many blockbuster drugs and exploit the growing number of cross-industry collaborations.
Connecting such a vast array of external data sources and extracting meaningful and actionable insights is a significant engineering feat, said Chris Venezia, Chief Revenue Officer. Our capabilities in this area and the fact that we allow our customers to configure the platform to meet their needs, means solution providers like Informa Pharma Intelligence can deliver tailor-made solutions to the market that combine their intelligence capabilities with next generation AI in a way that is meaningful to a specific customer. Together we are answering the demand that is coming from drug manufacturers and biotech firms looking for ways to cut market research costs, increase effectiveness and ultimately drive business growth with minimal risk.
The companies will be presenting the joint solution in an upcoming webinar, May 20, 2020 at 11AM EDT. Visit Informa Pharma Intelligence for more details and to register. About Informa Pharma Intelligence Informa Pharma Intelligence powers a full suite of analysis productsDatamonitor Healthcare, Sitetrove, Trialtrove, Pharmaprojects, Medtrack, Biomedtracker, Scrip, Pink Sheet and In Vivo to deliver the data needed by the pharmaceutical and biomedical industry to make decisions and create real-world opportunities for growth.
With more than 500 analysts keeping their fingers on the pulse of the industry, no key disease, clinical trial, drug approval or R&D project isnt covered through the breadth and depth of data available to customers. For more information visit pharmaintelligence.informa.com. About Signals Analytics: Signals Analytics is a next-generation advanced analytics configurable platform that extracts context from uncorrelated external data sources to uncover trends and predictive insights. Users of the platform include brand managers and business leaders, chief data officers, consumer and market insights professionals, IT and analytics experts, who experience faster time to market, lower cost to insight and fewer product modifications post-launch when incorporating Signals Analytics market intelligence into their planning processes. Trusted by an impressive roster of global brands including Procter & Gamble, Nestle, Johnson & Johnson, Bayer, Roche, Mars and others, Signals Analytics is redefining the world of market intelligence. For more information visit www.signals-analytics.com.
Media Contacts: Diffusion PR for Informa Pharma Intelligence email@example.com 646.571.0120
Chris Thatcher 5W Public Relations for Signals Analytics firstname.lastname@example.org or 646-430-5161